Nicolas Moosmann

Smarter drugs emerging in pancreatic cancer therapy

Contribution of platelets to tumour metastasis

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

Targeted treatments in colorectal cancer: state of the art and future perspectives

Colorectal cancer

Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer

Regulation of intestinal epithelial permeability by tight junctions

Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial

Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy

Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date

Cornerstones of CRISPR–Cas in drug discovery and therapy

Roles of transforming growth factor-α in mammary development and disease

Cancer Cells in Transit: The Vascular Interactions of Tumor Cells

Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis

Cancer Genome Landscapes

Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer

Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group

Cetuximab plus XELIRI or XELOX for First-Line Therapy of Metastatic Colorectal Cancer

The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial

Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group

Cetuximab in the treatment of metastatic colorectal cancer